Xiaoqin Wu, Xiude Fan, Megan R. McMullen, Tatsunori Miyata, Adam Kim, Vai Pathak, Jianguo Wu, Le Z. Day, Josiah E. Hardesty, Nicole Welch, Jaividhya Dasarathy, Daniela S. Allende, Arthur J. McCullough, Jon M. Jacobs, Daniel M. Rotroff, Srinivasan Dasarathy, Laura E. Nagy – 10 June 2022
When did you join AASLD?
I joined the American Association for the Study of Liver Diseases [AASLD] in 1957.
Describe what AASLD was like at the time you joined.
I believe AASLD had, at the time, approximately 150 members. Most of the topics were based on pathology. There was relatively little biochemistry, which was considered the advanced science of the day.
What do you feel is your greatest accomplishment which has contributed to the success of AASLD?
I would say there are two things. First, I was the inaugural Editor-in-Chief for the HEPATOLOGY journal. Its first issue debuted in January / February 1981. My second accomplishment was that I was the AASLD President in 1976.
What would people be surprised to learn about AASLD from "back in the day?"
Let me share with you about The Liver Meeting®. I attended my first meeting in 1957 in Chicago. I believe it was held at the Drake Hotel. The meeting was at most two days. At that time, presentations involved large glass slides. The meeting program was mimeographed. Essentially, attendees were asked to give 5 minute talks, and then a Q&A would follow. The cost to attend was $15.
What would you say is AASLD's great strength?
I would say AASLD's efforts to bridge advances in basic science with clinical medicine. AASLD achieves this through its annual programs, the HEPATOLOGY journal, meetings, special single topics and fellowships.
What would you say is AASLD's biggest accomplishment in its first 70 years?
Without question, AASLD's high standards with regards to its programs and activities.
How/where do you seen AASLD in the next 70 years?
Sometimes I do not think I can see beyond the end of my nose. That said, I hope that, for the benefit of patients, AASLD continues to support the ever-changing and advancing science of hepatology.
Monika Sarkar, Roxanna A. Irani – 9 June 2022
Doyeon Kim, Sangbin Han, You Sang Kim, Gyu‐Sung Choi, Jong Man Kim, Kyo Won Lee, Jae‐Hoon Ko, In Young Yoo, Justin Sangwook Ko, Mi Sook Gwak, Jae‐Won Joh, Gaab Soo Kim – 9 June 2022 – Bile duct surgeries are conventionally considered to promote bacterial contamination of the surgical field. However, liver transplantation recipients' bile produced by the newly implanted liver graft from healthy living donors may be sterile. We tested bacterial contamination of autologous blood salvaged before and after bile duct anastomosis (BDA) during living donor liver transplantation (LDLT).
C. Louwrens Braal, Robert J. Knegt, Agnes Jager, Stijn L. W. Koolen, Ron H. J. Mathijssen, Karel Eechoute – 9 June 2022 – Tamoxifen is a commonly prescribed drug in both early and metastatic breast cancer. Prospective studies in Asian populations demonstrated that tamoxifen‐related liver steatosis occurred in more than 30% of the patients within 2 years after start of treatment. No well‐designed prospective studies on potential tamoxifen‐related liver steatosis have been conducted in Caucasian patients so far.
Udeme D. Ekong, Sahithi Reddy, Nada Yazigi, Khalid Khan, Stuart Kaufman, Kimberly A. Chapman, Eyby Leon, Nicholas Ah Mew, Debra Regier, Erin MacLeod, Alexander Kroemer, Raffaelle Girlanda, Jason Hawksworth, Cal S. Matsumoto, Thomas M. Fishbein – 9 June 2022
Jun Xu, Ya Wang, Mina Khoshdeli, Matt Peach, Jen‐Chieh Chuang, Julie Lin, Wen‐Wei Tsai, Sangeetha Mahadevan, Wesley Minto, Lauri Diehl, Ruchi Gupta, Michael Trauner, Keyur Patel, Mazen Noureddin, Kris V. Kowdley, Aliya Gulamhusein, Christopher L. Bowlus, Ryan S. Huss, Robert P. Myers, Chuhan Chung, Andrew N. Billin – 9 June 2022
Anees Ahmad, Hamood Ur Rehman Chaudhry – 9 June 2022
8 June 2022
Zeinab Farhat, Neal D. Freedman, Joshua N. Sampson, Roni T. Falk, Jill Koshiol, Stephanie J. Weinstein, Demetrius Albanes, Rashmi Sinha, Erikka Loftfield – 7 June 2022 – Bile acids (BAs), major regulators of the gut microbiota, may play an important role in hepatobiliary cancer etiology. However, few epidemiologic studies have comprehensively examined associations between BAs and liver or biliary tract cancer.
